Compare IDEXX Laboratories, Inc. (IDXX) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Royal Caribbean Cruises Ltd — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Royal Caribbean Cruises Ltd trades at $282 (market cap $75.26B). The key difference: Royal Caribbean Cruises Ltd is the larger of the two by market cap, and Royal Caribbean Cruises Ltd pays a 2.13% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Royal Caribbean Cruises Ltd for 85 Days on average.
| IDXX | RCL | |
|---|---|---|
Market Cap | $40.43B | $75.26B |
Volume | 692,164 | 1,958,628 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $348.03 |
52-Week Low | $504.70 | $230.30 |
Typical Hold Time | 46 Days | 85 Days |
Enterprise Value | $41.32B | $97.91B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Royal Caribbean (RCL) trades at $282.26, showing minimal daily movement (-0.04%) amid strong fundamental performance. The stock maintains a bullish technical outlook with support at $279 and resistance at $284. Recent earnings beats in Q1 and Q2 2026, coupled with robust revenue growth from $8.8B in 2022 to $17.9B in 2025, highlight operational strength. The company's expansion into resort markets through the $3B Sandals acquisition adds growth diversification while analyst consensus remains positive with a $346.67 price target.
RCL presents a compelling growth story with expanding profit margins and strategic diversification, though elevated debt levels and fuel cost sensitivity pose moderate risks. The stock's current valuation at 17.38x P/E appears reasonable given 45.33% ROE and consistent earnings outperformance. Near-term catalysts include Q3 2026 earnings and continued execution on the Sandals integration, while macroeconomic pressures on travel demand represent the primary headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
